- Home
- OESX vs NNVC Comparison
OESX vs NNVC Comparison
Compare OESX & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OESX
- NNVC
- Stock Information
- Founded
- OESX 1996
- NNVC 2005
- Country
- OESX United States
- NNVC United States
- Employees
- OESX N/A
- NNVC N/A
- Industry
- OESX Building Products
- NNVC Biotechnology: Pharmaceutical Preparations
- Sector
- OESX Consumer Discretionary
- NNVC Health Care
- Exchange
- OESX Nasdaq
- NNVC Nasdaq
- Market Cap
- OESX 19.3M
- NNVC 22.5M
- IPO Year
- OESX 2007
- NNVC N/A
- Fundamental
- Price
- OESX $0.60
- NNVC $1.68
- Analyst Decision
- OESX Strong Buy
- NNVC
- Analyst Count
- OESX 2
- NNVC 0
- Target Price
- OESX $1.75
- NNVC N/A
- AVG Volume (30 Days)
- OESX 92.3K
- NNVC 330.6K
- Earning Date
- OESX 08-06-2025
- NNVC 05-15-2025
- Dividend Yield
- OESX N/A
- NNVC N/A
- EPS Growth
- OESX N/A
- NNVC N/A
- EPS
- OESX N/A
- NNVC N/A
- Revenue
- OESX $79,720,000.00
- NNVC N/A
- Revenue This Year
- OESX $7.16
- NNVC N/A
- Revenue Next Year
- OESX $16.23
- NNVC N/A
- P/E Ratio
- OESX N/A
- NNVC N/A
- Revenue Growth
- OESX N/A
- NNVC N/A
- 52 Week Low
- OESX $0.55
- NNVC $0.94
- 52 Week High
- OESX $1.10
- NNVC $2.50
- Technical
- Relative Strength Index (RSI)
- OESX 48.93
- NNVC 60.67
- Support Level
- OESX $0.59
- NNVC $1.54
- Resistance Level
- OESX $0.66
- NNVC $1.79
- Average True Range (ATR)
- OESX 0.03
- NNVC 0.10
- MACD
- OESX 0.00
- NNVC 0.02
- Stochastic Oscillator
- OESX 43.64
- NNVC 75.56
About OESX Orion Energy Systems Inc.
Orion Energy Systems Inc is a developer, manufacturer, and seller of lighting and energy management systems. The company segments include Orion Lighting Segment, Orion Maintenance Segment and Orion Electric Vehicle Charging Segment. It derives maximum revenue from Lighting Segment.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.